|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Mr. Michael T. Heffernan||Founder, Chairman, Pres, CEO, Treasurer & Sec.||736k||N/A||1964|
|Mr. Paul Brannelly||Exec. VP, CFO & Principal Accounting Officer||452,07k||N/A||1973|
|Mr. Joseph J. Ciaffoni||Exec. VP & COO||N/A||N/A||1972|
|Dr. Alison B. Fleming||Exec. VP & Chief Technology Officer||N/A||N/A||1975|
|Mr. Scott Dreyer||Sr. VP of Sales, Marketing, Commercial Capabilities & Training||N/A||N/A||N/A|
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.
El ISS Governance QualityScore de Collegium Pharmaceutical, Inc., a día 1 de marzo de 2018, es 8. Las puntuaciones base son Auditoría: 2; Tablero: 9; Derechos de los accionistas: 5; Compensación: 8.